Anti-CD133 Antibody is an antibody that specifically binds to CD133, a cell surface protein known as cluster of differentiation 133. CD133 is primarily found on stem cells, including those of the blood and epithelial tissues. This antibody is widely used in research to isolate and study stem cells, particularly in the context of cancer research, where CD133 has been associated with tumor initiating cells. It is also explored for its potential in regenerative medicine and tissue engineering due to CD133's presence on cells with regenerative potential.

The global Anti-CD133 Antibody market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Anti-CD133 Antibody Industry Forecast” looks at past sales and reviews total world Anti-CD133 Antibody sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-CD133 Antibody sales for 2024 through 2030. With Anti-CD133 Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-CD133 Antibody industry.

This Insight Report provides a comprehensive analysis of the global Anti-CD133 Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-CD133 Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-CD133 Antibody market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-CD133 Antibody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-CD133 Antibody.

The industry trend for Anti-CD133 Antibody has seen a rise as it becomes an increasingly important tool in stem cell research and oncology. The antibody's role in identifying and isolating cancer stem cells has implications for the development of novel therapeutics targeting these cells, which are believed to be responsible for tumor recurrence and resistance to treatment. Additionally, the potential for CD133 in regenerative applications is driving the demand for high-quality Anti-CD133 Antibody products. As research progresses and the functions of CD133 in various diseases are further understood, the industry trend for this antibody is expected to continue growing.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-CD133 Antibody market by product type, application, key players and key regions and countries.

• Monoclonal Antibody
• Polyclonal Antibody

• Biotechnology
• Medical
• University
• Others

This report also splits the market by region:

• United States
• Canada
• Mexico
• Brazil

• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

• Germany
• France
• UK
• Italy
• Russia

• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• BosterBio
• GeneTex
• ProSci
• Bioss
• Absolute Antibody
• MyBioSource
• Biorbyt
• Thermo Fisher Scientific
• R&D Systems
• Novus Biologicals
• BioLegend
• G Biosciences
• Cell Signaling Technology
• RayBiotech
• HUABIO
• Abeomics
• Proteintech Group
• Miltenyi Biotec
• Wuhan Fine Biotech
• NSJ Bioreagents
• Bethyl Laboratories
• OriGene Technologies
• Signalway Antibody
• Abnova
• Bioassay Technology Laboratory
• AAT Bioquest
• Sino Biological
• ProteoGenix